NSPR

InspireMD, Inc. (NSPR) | Rumor.io

InspireMD

NSPR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,922

Bullish sentiment (50-day avg)82%

Price to earnings ratio-0.91

Market capitalization32.3M

Earnings per share-0.61

Dividend yield (TTM)—

Revenue (annual)9M

Net income (annual)-48.8M

Social

What share of all stock conversation is about NSPR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Aug 17

InspireMD's Q2 2026 revenue was flat at $1.8M, with international revenue up 21% but US revenue going negative due to a voluntary recall.
The recall led to a gross loss of $774K and a net loss of $14.3M, with $30.4M in cash on hand.
The company's Q2 earnings were marked by a U.S. recall that erased momentum, with the author suggesting that delisting may be a practical solution.

Generated by AI

Sentiment

Of the messages about NSPR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0% -100	70.52% -3.37
Bearish	100%	100%	100% new	29.48% +3.37

Bullish· Jun 24

InspireMD's CGuard Prime stent has a low adverse event rate (1.95% at 1 year) and restenosis rate (0.7%), driven by its MicroNet technology, making it a strong contender in carotid stenting.
The company has a clean balance sheet with no debt and $17.9M in warrants, positioning it for a successful U.S. commercial launch of its stent.
The U.S. market for carotid stents is larger than the entire worldwide market, making InspireMD's product a potentially lucrative opportunity.

Bearish· May 1

$NSPR's recall and approval may not have a significant impact on the stock's performance, as it has been dropping since approval.
The company's commercial sales in the US are likely struggling, which may lead to a further decline in the stock price to around 70 cents.
The stock's recent performance and the timing of the news release may indicate that the market is already aware of the issues and has priced them in, making the recall and approval news less impactful.

Generated by AI

Topics

Of the messages about NSPR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	57.94%
Earnings	—	—	—	23.36%
Analysts	—	—	—	9.35%
Controversies	—	—	—	3.74%
Macro	—	—	—	0%
Technical Analysis	—	—	—	5.61%

Earnings· Nov 7

InspireMD, Inc. reported Q3 EPS of $(0.19), a significant improvement from $(0.85) in the same quarter last year.
The company's sales reached $718K, a substantial year-over-year increase from $469K.
InspireMD's Q3 results show a notable turnaround in profitability and revenue growth.

Announcements· May 15

InspireMD, Inc. (NSPR) has secured funding for at least the rest of 2023 through a private placement of up to $113.6 million.
The company has established an office in Miami, Florida, and is advancing CGuard commercialization in the US, with potential hiring updates to come.
InspireMD's private placement was led by Marshall Wace, a hedge fund recognized as one of the world's largest managers, with the company's securities purchase agreement providing up to $113.6 million in gross proceeds.

Technical Analysis· Feb 11

$NSPR has broken through a triangle formation and is awaiting a potential breakout to $1.60 and subsequently $1.80.
The stock has strong price action, testing the $1.50 range and consolidating at $1.30s, with a possible next leg up.
The RSI is high, but the stock's strong volume and low short interest suggest a continued upward trend, with potential resistance in the $1.75-$1.80 area.

Generated by AI

Community

Of the messages about NSPR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	55.67%
Newcomers	0%	0%	0%	44.33%

Regulars· May 16

InspireMD, Inc. has reported its first quarter 2023 financial results, showing a GAAP EPS of -$0.53, beating estimates by $0.15, and revenue of $1.24M, beating estimates by $0.24M.
Several company insiders have made significant purchases of shares, including Gary S Roubin, Thomas J Kester, Paul Stuka, and Michael Berman, indicating a positive outlook on the company's future.
InspireMD, Inc.'s stock price is experiencing volatility, with a 11.90% increase in the last 20 minutes and a -10.87% drop in the pre-market, following the release of its first quarter 2023 financial results.

Newcomers· May 15

New investors are focused on the potential for $NSPR to break above $2.03, with some seeing it as a buy signal.
The company's recent announcement of a private placement of up to $113.6 million is being seen as a positive development for InspireMD, with some investors expecting a price increase.
Some newcomers are monitoring the stock's low float and high short float, with one user noting that a pullback in $NSPR could provide a safer entry point.

Generated by AI

News

InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know

InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1mo agoYahoo Finance

InspireMD, Inc. Q2 2026 Earnings Call Summary

Moby summary of InspireMD, Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Earnings call transcript: InspireMD Q2 2026 revenue miss weighs on shares

1mo agoInvesting.com

Also Discussed

Investors talking about NSPR also mention

#	Name	Attention
1	China Pharma Holdings, Inc.CPHI	0%new
2	NVCN - Neovasc Inc.	——
3	Oragenics Inc.OGEN	0%0
4	Jaguar Health, Inc.JAGX	0.02%-0.02
5	AVGR - Avinger, Inc.	——
6	My Size, Inc.MYSZ	0%new
7	Top Ships Inc.TOPS	0%+0
8	TTNP - Titan Pharmaceuticals, Inc.	——
9	YTEN - Yield10 Bioscience, Inc.	——
10	vTv Therapeutics Inc. Class A Common StockVTVT	0%new

InspireMD, Inc.

Healthcare
Medical Devices

InspireMD, Inc. is a medical device company that develops and commercializes products for the treatment of carotid artery disease and other vascular conditions. The company’s portfolio centers on its proprietary CGuard™ carotid stent platform and MicroNet™ mesh technology, which are designed to support embolic protection during and after stenting procedures. InspireMD’s current products include carotid embolic prevention and stent systems used in vascular and neurovascular interventions, with applications across stroke prevention and related artery treatment settings. The company serves physicians, hospitals, and healthcare providers in multiple international markets, including the United States and select regions in Europe, the Middle East, Latin America, and Asia Pacific. InspireMD plays a specialized role in the medical technology market by focusing on device-based solutions for complex carotid and coronary care.

Website

Location

6303 Waterford District Drive

Miami, FL, 33126

United States

Social

What share of all stock conversation is about NSPR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Aug 17

InspireMD's Q2 2026 revenue was flat at $1.8M, with international revenue up 21% but US revenue going negative due to a voluntary recall.
The recall led to a gross loss of $774K and a net loss of $14.3M, with $30.4M in cash on hand.
The company's Q2 earnings were marked by a U.S. recall that erased momentum, with the author suggesting that delisting may be a practical solution.

Generated by AI

Sentiment

Of the messages about NSPR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0% -100	70.52% -3.37
Bearish	100%	100%	100% new	29.48% +3.37

Bullish· Jun 24

InspireMD's CGuard Prime stent has a low adverse event rate (1.95% at 1 year) and restenosis rate (0.7%), driven by its MicroNet technology, making it a strong contender in carotid stenting.
The company has a clean balance sheet with no debt and $17.9M in warrants, positioning it for a successful U.S. commercial launch of its stent.
The U.S. market for carotid stents is larger than the entire worldwide market, making InspireMD's product a potentially lucrative opportunity.

Bearish· May 1

$NSPR's recall and approval may not have a significant impact on the stock's performance, as it has been dropping since approval.
The company's commercial sales in the US are likely struggling, which may lead to a further decline in the stock price to around 70 cents.
The stock's recent performance and the timing of the news release may indicate that the market is already aware of the issues and has priced them in, making the recall and approval news less impactful.

Generated by AI

Topics

Of the messages about NSPR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	57.94%
Earnings	—	—	—	23.36%
Analysts	—	—	—	9.35%
Controversies	—	—	—	3.74%
Macro	—	—	—	0%
Technical Analysis	—	—	—	5.61%

Earnings· Nov 7

InspireMD, Inc. reported Q3 EPS of $(0.19), a significant improvement from $(0.85) in the same quarter last year.
The company's sales reached $718K, a substantial year-over-year increase from $469K.
InspireMD's Q3 results show a notable turnaround in profitability and revenue growth.

Announcements· May 15

InspireMD, Inc. (NSPR) has secured funding for at least the rest of 2023 through a private placement of up to $113.6 million.
The company has established an office in Miami, Florida, and is advancing CGuard commercialization in the US, with potential hiring updates to come.
InspireMD's private placement was led by Marshall Wace, a hedge fund recognized as one of the world's largest managers, with the company's securities purchase agreement providing up to $113.6 million in gross proceeds.

Technical Analysis· Feb 11

$NSPR has broken through a triangle formation and is awaiting a potential breakout to $1.60 and subsequently $1.80.
The stock has strong price action, testing the $1.50 range and consolidating at $1.30s, with a possible next leg up.
The RSI is high, but the stock's strong volume and low short interest suggest a continued upward trend, with potential resistance in the $1.75-$1.80 area.

Generated by AI

Community

Of the messages about NSPR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	55.67%
Newcomers	0%	0%	0%	44.33%

Regulars· May 16

InspireMD, Inc. has reported its first quarter 2023 financial results, showing a GAAP EPS of -$0.53, beating estimates by $0.15, and revenue of $1.24M, beating estimates by $0.24M.
Several company insiders have made significant purchases of shares, including Gary S Roubin, Thomas J Kester, Paul Stuka, and Michael Berman, indicating a positive outlook on the company's future.
InspireMD, Inc.'s stock price is experiencing volatility, with a 11.90% increase in the last 20 minutes and a -10.87% drop in the pre-market, following the release of its first quarter 2023 financial results.

Newcomers· May 15

New investors are focused on the potential for $NSPR to break above $2.03, with some seeing it as a buy signal.
The company's recent announcement of a private placement of up to $113.6 million is being seen as a positive development for InspireMD, with some investors expecting a price increase.
Some newcomers are monitoring the stock's low float and high short float, with one user noting that a pullback in $NSPR could provide a safer entry point.

Generated by AI

InspireMD

Social

Aug 17

Bullish· Jun 24

Bearish· May 1

Earnings· Nov 7

Announcements· May 15

Technical Analysis· Feb 11

Regulars· May 16

Newcomers· May 15

InspireMD amends warrants tied to FDA approval timeline

Full Transcript: InspireMD Q2 2026 Earnings Call

InspireMD at H.C. Wainwright conference: eyeing carotid market share

InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know

InspireMD, Inc. Q2 2026 Earnings Call Summary

Earnings call transcript: InspireMD Q2 2026 revenue miss weighs on shares

Also Discussed

InspireMD, Inc.

Company Information

Location

InspireMD amends warrants tied to FDA approval timeline

Full Transcript: InspireMD Q2 2026 Earnings Call

InspireMD at H.C. Wainwright conference: eyeing carotid market share

InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know

InspireMD, Inc. Q2 2026 Earnings Call Summary

Earnings call transcript: InspireMD Q2 2026 revenue miss weighs on shares

Also Discussed

Social

Aug 17

Bullish· Jun 24

Bearish· May 1

Earnings· Nov 7

Announcements· May 15

Technical Analysis· Feb 11

Regulars· May 16

Newcomers· May 15